secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-264644
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Q3 net loss $38.3M ($0.65/sh); Phase 3 EMPEROR >20 randomized
-------------------------------------------------------------------

- Net loss $38.3M ($0.65/sh) vs $26.4M ($0.47) in Q3 2024; revenue $10.6M vs $4.9M.
- Cash $328.6M as of Sep 30; $48.7M from Oct share sales; funded to mid-2028.
- Phase 3 EMPEROR: >20 patients randomized, ~35 in screening; enrollment on track for H2 2026.
- FDA meeting planned before year-end to discuss expedited regulatory pathways for zorevunersen.
- Ian F. Smith appointed permanent CEO (was interim); Arthur Tzianabos resumes Chairman role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525264644/0001193125-25-264644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525264644/stok-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-264644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer